144 related articles for article (PubMed ID: 14722240)
1. Mechanism of HIV-1 integrase inhibition by styrylquinoline derivatives in vitro.
Deprez E; Barbe S; Kolaski M; Leh H; Zouhiri F; Auclair C; Brochon JC; Le Bret M; Mouscadet JF
Mol Pharmacol; 2004 Jan; 65(1):85-98. PubMed ID: 14722240
[TBL] [Abstract][Full Text] [Related]
2. Nuclear import of HIV-1 integrase is inhibited in vitro by styrylquinoline derivatives.
Mousnier A; Leh H; Mouscadet JF; Dargemont C
Mol Pharmacol; 2004 Oct; 66(4):783-8. PubMed ID: 15247318
[TBL] [Abstract][Full Text] [Related]
3. Dissecting Tn5 transposition using HIV-1 integrase diketoacid inhibitors.
Czyz A; Stillmock KA; Hazuda DJ; Reznikoff WS
Biochemistry; 2007 Sep; 46(38):10776-89. PubMed ID: 17725323
[TBL] [Abstract][Full Text] [Related]
4. Styrylquinoline derivatives: a new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells.
Mekouar K; Mouscadet JF; Desmaële D; Subra F; Leh H; Savouré D; Auclair C; d'Angelo J
J Med Chem; 1998 Jul; 41(15):2846-57. PubMed ID: 9667973
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 integrase preassembled on donor DNA is refractory to activity stimulation by LEDGF/p75.
Yu F; Jones GS; Hung M; Wagner AH; MacArthur HL; Liu X; Leavitt S; McDermott MJ; Tsiang M
Biochemistry; 2007 Mar; 46(10):2899-908. PubMed ID: 17298035
[TBL] [Abstract][Full Text] [Related]
6. Hyrtiosal, from the marine sponge Hyrtios erectus, inhibits HIV-1 integrase binding to viral DNA by a new inhibitor binding site.
Du L; Shen L; Yu Z; Chen J; Guo Y; Tang Y; Shen X; Jiang H
ChemMedChem; 2008 Jan; 3(1):173-80. PubMed ID: 17943714
[TBL] [Abstract][Full Text] [Related]
7. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes.
Grobler JA; Stillmock K; Hu B; Witmer M; Felock P; Espeseth AS; Wolfe A; Egbertson M; Bourgeois M; Melamed J; Wai JS; Young S; Vacca J; Hazuda DJ
Proc Natl Acad Sci U S A; 2002 May; 99(10):6661-6. PubMed ID: 11997448
[TBL] [Abstract][Full Text] [Related]
8. Potent inhibitors of HIV-1 integrase display a two-step, slow-binding inhibition mechanism which is absent in a drug-resistant T66I/M154I mutant.
Garvey EP; Schwartz B; Gartland MJ; Lang S; Halsey W; Sathe G; Carter HL; Weaver KL
Biochemistry; 2009 Feb; 48(7):1644-53. PubMed ID: 19178153
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 integrase complexes with DNA dissociate in the presence of short oligonucleotides conjugated to acridine.
Pinskaya M; Romanova E; Volkov E; Deprez E; Leh H; Brochon JC; Mouscadet JF; Gottikh M
Biochemistry; 2004 Jul; 43(27):8735-43. PubMed ID: 15236582
[TBL] [Abstract][Full Text] [Related]
10. Exploring binding mode for styrylquinoline HIV-1 integrase inhibitors using comparative molecular field analysis and docking studies.
Ma XH; Zhang XY; Tan JJ; Chen WZ; Wang CX
Acta Pharmacol Sin; 2004 Jul; 25(7):950-8. PubMed ID: 15210071
[TBL] [Abstract][Full Text] [Related]
11. Effects of nucleotide analogues on human immunodeficiency virus type 1 integrase.
Mazumder A; Neamati N; Sommadossi JP; Gosselin G; Schinazi RF; Imbach JL; Pommier Y
Mol Pharmacol; 1996 Apr; 49(4):621-8. PubMed ID: 8609889
[TBL] [Abstract][Full Text] [Related]
12. Symmetrical 1-pyrrolidineacetamide showing anti-HIV activity through a new binding site on HIV-1 integrase.
Du L; Zhao YX; Yang LM; Zheng YT; Tang Y; Shen X; Jiang HL
Acta Pharmacol Sin; 2008 Oct; 29(10):1261-7. PubMed ID: 18817633
[TBL] [Abstract][Full Text] [Related]
13. [HIV-1 integrase inhibition by dimeric bisbenzimidazoles having different spacers].
Korolev SP; Tashlitskiĭ VN; Smolov MA; Gromyko AV; Zhuze AL; Agapkina IuIu; Gottikh MB
Mol Biol (Mosk); 2010; 44(4):718-27. PubMed ID: 20873232
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of 5-(1-H or 1-alkyl-5-oxopyrrolidin-3-yl)-8-hydroxy-[1,6]-naphthyridine-7-carboxamide inhibitors of HIV-1 integrase.
Melamed JY; Egbertson MS; Varga S; Vacca JP; Moyer G; Gabryelski L; Felock PJ; Stillmock KA; Witmer MV; Schleif W; Hazuda DJ; Leonard Y; Jin L; Ellis JD; Young SD
Bioorg Med Chem Lett; 2008 Oct; 18(19):5307-10. PubMed ID: 18774711
[TBL] [Abstract][Full Text] [Related]
15. A platform for designing HIV integrase inhibitors. Part 2: a two-metal binding model as a potential mechanism of HIV integrase inhibitors.
Kawasuji T; Fuji M; Yoshinaga T; Sato A; Fujiwara T; Kiyama R
Bioorg Med Chem; 2006 Dec; 14(24):8420-9. PubMed ID: 17005407
[TBL] [Abstract][Full Text] [Related]
16. Beta-diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors.
Dayam R; Sanchez T; Clement O; Shoemaker R; Sei S; Neamati N
J Med Chem; 2005 Jan; 48(1):111-20. PubMed ID: 15634005
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of styrylbenzofuran derivatives as styrylquinoline analogues for HIV-1 integrase inhibitor.
Yoo H; Lee JY; Park JH; Chung BY; Lee YS
Farmaco; 2003 Dec; 58(12):1243-50. PubMed ID: 14630234
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human immunodeficiency virus type I integrase by naphthamidines and 2-aminobenzimidazoles.
Middleton T; Lim HB; Montgomery D; Rockway T; Tang H; Cheng X; Lu L; Mo H; Kohlbrenner WE; Molla A; Kati WM
Antiviral Res; 2004 Oct; 64(1):35-45. PubMed ID: 15451177
[TBL] [Abstract][Full Text] [Related]
19. Scintillation proximity assays for mechanistic and pharmacological analyses of HIV-1 integration.
Grobler JA; Stillmock KA; Hazuda DJ
Methods; 2009 Apr; 47(4):249-53. PubMed ID: 19285556
[TBL] [Abstract][Full Text] [Related]
20. The use of a new in vitro reaction substrate reproducing both U3 and U5 regions of the HIV-1 3'-ends increases the correlation between the in vitro and in vivo effects of the HIV-1 integrase inhibitors.
Tramontano E; Onidi L; Esposito F; Badas R; La Colla P
Biochem Pharmacol; 2004 May; 67(9):1751-61. PubMed ID: 15081874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
